Drug Sponsors

Galapagos subsidiary BioFocus collaborates with Ono on CNS drug discovery

Tuesday, September 4, 2012 12:46 PM

Galapagos’ service division BioFocus and Ono Pharmaceutical have signed a new collaboration agreement focused on discovering novel drugs for CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates.

More... »

Merck Serono spin-off Quartz Bio to offer biomarker data analysis

Tuesday, September 4, 2012 12:41 PM

Merck Serono, a division of Merck, has created Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process, as it enables the identification of patient profiles most responsive to a given treatment.

More... »

Allergan opens NJ facility

Tuesday, September 4, 2012 12:39 PM

Irvine, Calif.-based Allergan has opened its first large facility in New Jersey, the R&D Center in Bridgewater, N.J.

More... »

Valeant to acquire Medicis, strengthen dermatology offerings

Tuesday, September 4, 2012 12:36 PM

Montreal-based Valeant Pharmaceuticals International and Medicis Pharmaceutical of Scottsdale, Ariz., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the boards of both companies. The $44 price represents a 39% premium to Medicis' closing share price Friday, Aug. 31, the last trading day prior to the announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

More... »

U.K. general public has fundamental misunderstanding of cost and value of medicines

Monday, September 3, 2012 08:00 AM

A new survey commissioned by the ABPI, has revealed that the British public misunderstands the cost and value of medicines in the U.K.

More... »

Galectin to relocate headquarters to Atlanta

Friday, August 31, 2012 01:28 PM

Galectin Therapeutics, a developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be relocating its corporate offices to Atlanta, Ga., effective October 1, 2012, while maintaining a laboratory-based effort in the Boston area.

More... »

Aerpio completes $27M Series A Financing for diabetic macular edema

Thursday, August 30, 2012 02:07 PM

Aerpio Therapeutics, a clinical-stage biopharmaceutical spin off of Akebia Therapeutics based in Cincinnati, Ohio, has closed a $27 million Series A financing.

More... »

Sunovion to acquire Elevation Pharma

Thursday, August 30, 2012 01:42 PM

Sunovion Pharmaceuticals, a Marlborough, Mass.-based pharmaceutical company focused on the central nervous system and respiratory disease, has agreed to acquire San Diego-based Elevation Pharmaceuticals, which specializes in the development of new aerosol therapies for patients with respiratory diseases.

More... »

Oncologists restrict pharmaceutical sales rep access at accelerating rates

Wednesday, August 29, 2012 01:37 PM

As more pharmaceutical companies prepare to bring new oncology drugs to market, their sales representatives face a rising hurdle—oncologists are reducing the number of times they will see them.

More... »

Novira secures $23M Series A financing for Hep B, HIV

Wednesday, August 29, 2012 11:12 AM

Novira Therapeutics, an antiviral drug discovery company, has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

More... »